OBJECTIVE: To evaluate inflammatory responses induced via intra-articular recombinant human interleukin (IL)-1beta treatment in horses receiving a dietary nutraceutical (DN; composed of mussel, shark cartilage, abalone, and Biota orientalis lipid extract) and assess the clinical effects of long-term DN administration. ANIMALS: 22 healthy horses. PROCEDURES: 12 horses were fed 0, 15, 45, or 75 mg of DN (3 horses/treatment) daily for 84 days. General health and clinicopathologic variables were monitored at intervals. Ten other horses received 0 or 15 g of DN/d (5 horses/treatment) for 29 days (beginning day -14). One intercarpal joint in each horse was injected twice with IL-1beta (10 and 100 ng on days 0 and 1, respectively), and the contralateral joint was similarly injected with saline (0.9% NaCl) solution. Synovial fluid prostaglandin E(2) (PGE(2)), sulfated glycosaminoglycan (GAG), nitric oxide (NO), and protein concentrations and leukocyte counts were analyzed before and at intervals after injections. RESULTS: Administration of the DN (up to 75 g/d) to horses for 84 days did not induce any adverse effects. In the other experiment, synovial fluid PGE(2), GAG, and protein concentrations and leukocyte count increased after intra-articular injections of IL-1beta (compared with effects of saline solution injections) in horses that received no DN; NO concentration was not affected. In horses that were fed the DN, intra-articular IL-1beta injections did not induce significant increases in synovial fluid PGE(2) and GAG concentrations. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that administration of the DN may be useful in preventing inflammation associated with arthritis and degenerative joint disease in horses.
OBJECTIVE: To evaluate inflammatory responses induced via intra-articular recombinant humaninterleukin (IL)-1beta treatment in horses receiving a dietary nutraceutical (DN; composed of mussel, shark cartilage, abalone, and Biota orientalis lipid extract) and assess the clinical effects of long-term DN administration. ANIMALS: 22 healthy horses. PROCEDURES: 12 horses were fed 0, 15, 45, or 75 mg of DN (3 horses/treatment) daily for 84 days. General health and clinicopathologic variables were monitored at intervals. Ten other horses received 0 or 15 g of DN/d (5 horses/treatment) for 29 days (beginning day -14). One intercarpal joint in each horse was injected twice with IL-1beta (10 and 100 ng on days 0 and 1, respectively), and the contralateral joint was similarly injected with saline (0.9% NaCl) solution. Synovial fluid prostaglandin E(2) (PGE(2)), sulfated glycosaminoglycan (GAG), nitric oxide (NO), and protein concentrations and leukocyte counts were analyzed before and at intervals after injections. RESULTS: Administration of the DN (up to 75 g/d) to horses for 84 days did not induce any adverse effects. In the other experiment, synovial fluid PGE(2), GAG, and protein concentrations and leukocyte count increased after intra-articular injections of IL-1beta (compared with effects of saline solution injections) in horses that received no DN; NO concentration was not affected. In horses that were fed the DN, intra-articularIL-1beta injections did not induce significant increases in synovial fluid PGE(2) and GAG concentrations. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that administration of the DN may be useful in preventing inflammation associated with arthritis and degenerative joint disease in horses.
Authors: Raphael Labens; B Duncan X Lascelles; Anna N Charlton; Nicole R Ferrero; Arnaud J Van Wettere; Xin-Riu Xia; Anthony T Blikslager Journal: Tissue Barriers Date: 2013-04-01
Authors: E van de Water; M Oosterlinck; M Dumoulin; N M Korthagen; P R van Weeren; J van den Broek; H Everts; F Pille; D A van Doorn Journal: Equine Vet J Date: 2016-10-13 Impact factor: 2.888
Authors: Charles T Eason; Serean L Adams; Jonathan Puddick; Donato Romanazzi; Matthew R Miller; Nick King; Sarah Johns; Elizabeth Forbes-Blom; Paul A Hessian; Lisa K Stamp; Michael A Packer Journal: Vet Sci Date: 2018-03-27